Caris Life Sciences, Inc. (CAI) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, Caris Life Sciences reported revenue of $812.0M. Net income was -$68.1M (a -8.4% net margin), or -$3.22 per diluted share. Gross margin was 5.6% and operating margin was 5.6%. Operating activities generated $83.2M of cash, leaving $66.9M of free cash flow. At fiscal year end, Caris Life Sciences held $1.13B in total assets against $548.4M in total liabilities, including $796.3M of cash and equivalents.
Open the full interactive Caris Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Caris Life Sciences Key Stats
| Share Price | $29.53 |
|---|---|
| Market Cap | $8.35B |
| 52-Week Range | $14.55 – $32.27 |
| Shares Outstanding | 282.9 million (basic, 2026 Q2) |
Caris Life Sciences Income Statement
| FY 2025 | |
|---|---|
| Revenue | $812.0M |
| Cost of Goods Sold | $766.9M |
| Gross Profit | $45.1M |
| Operating Income | $45.1M |
| Pre-Tax Income | -$68.1M |
| Income Tax | $0 |
| Net Income | -$68.1M |
| Diluted EPS | -$3.22 |
Caris Life Sciences Quarterly Results
| 2025 Q2 | 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $181.4M | $216.8M | $216.2M | $263.7M |
| Net Income | -$71.8M | $24.3M | -$510,000 | -$637,000 |
| Diluted EPS | -$7.97 | $0.08 | — | — |
Caris Life Sciences Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $796.3M |
| Current Assets | $997.8M |
| Total Assets | $1.13B |
| Current Liabilities | $127.1M |
| Total Long-Term Debt | $379.0M |
| Total Liabilities | $548.4M |
| Shareholders' Equity | $577.3M |
Caris Life Sciences Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | $83.2M |
| Cash From Investing | -$16.3M |
| Cash From Financing | $665.0M |
| Free Cash Flow | $66.9M |
Figures from Caris Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Caris Life Sciences financials page for every line item.
Caris Life Sciences Company Profile
| Ticker | CAI |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Irving, Texas |
| Incorporated in | Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002019410 |
Frequently Asked Questions
What was Caris Life Sciences' revenue in fiscal 2025?
Caris Life Sciences (CAI) reported revenue of $812.0M for fiscal 2025.
What was Caris Life Sciences' net income in fiscal 2025?
Caris Life Sciences reported net income of -$68.1M for fiscal 2025.
What was Caris Life Sciences' earnings per share (EPS) in fiscal 2025?
Caris Life Sciences' diluted EPS was -$3.22 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Caris Life Sciences generate in fiscal 2025?
Caris Life Sciences generated $66.9M of free cash flow in fiscal 2025.
What was Caris Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Caris Life Sciences reported revenue of $263.7M.
How much debt does Caris Life Sciences have?
Caris Life Sciences reported $379.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Caris Life Sciences are outstanding?
Caris Life Sciences reported a weighted average of 282.9 million basic shares outstanding in 2026 Q2.
What is Caris Life Sciences' market cap?
Based on its latest closing price, Caris Life Sciences (CAI) has a market capitalization of about $8.35B.
When does Caris Life Sciences' fiscal year end?
Caris Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Caris Life Sciences headquartered?
Caris Life Sciences lists its business address in Irving, Texas in its SEC filings.